SHP2 inhibitors alone are susceptible to resistance in neuroblastoma, however, dual inhibition of SHP2 and the RAS effectors RAF, MEK, or ERK demonstrated synergistic effects (71). Here, PTPN11 is linked to neuroblastoma.